Activin E, body fat distribution, and insulin resistance: human genetics, liver–adipose communication, and translational perspectives
Insulin resistance (IR) contributes to type 2 diabetes (T2DM), metabolic dysfunction-associated steatotic liver disease and cardiovascular disease. Human genetics and preclinical studies link the hepatokine activin E, encoded by INHBE, and its type I receptor ALK7 to body-fat distribution, adipose lipolysis and metabolic control. Large exome-sequencing studies associate heterozygous INHBE predicted loss-of-function (pLOF) variants with lower body mass index-adjusted waist-to-hip ratio; one multi-ancestry study also reported more favorable metabolic traits and approximately 28% lower odds of T2DM. ACVR1C coding variants show similar associations, although ALK7 receives input from several ligands. Hepatocytes upregulate INHBE during non-esterified fatty-acid load and cellular stress. In mouse and adipocyte systems, secreted activin E signals through adipocyte ALK7 complexes containing ActRIIA or ActRIIB, activates SMAD2/3, and suppresses PPARγ-dependent lipolytic programs and β3-adrenergic signaling. This feedback preserves lipid stores during fasting but may promote adipocyte hypertrophy and catecholamine resistance in obesity. Lower activin E-ALK7 signaling is associated with more favorable fat distribution in human genetics, whereas reduced fat mass in mouse loss-of-function models can coexist with hepatic lipid accumulation and impaired insulin action. In one constitutive high-fat-fed mouse model, complete Inhbe loss increased hepatic lipid burden and produced a lean MASH-like phenotype. Durable efficacy and long-term hepatic safety require clinical validation. This review examines activin E biology, human genetics and preclinical evidence at three intervention levels: the activin E ligand, the ALK7 receptor and shared type II receptors, with particular attention to hepatic safety.
Authors
- Na Zhao (ORCID: https://orcid.org/0000-0001-6948-8698)
- Zhuoshi Yang
- Jian Ma
Institutions
- Heilongjiang University of Chinese Medicine (CN)
- First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fendo.2026.2005408
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Heilongjiang University of Chinese Medicine